Recruitment

Recruitment Status
Terminated
Estimated Enrollment
1200

Summary

Conditions
Type 2 Diabetes Mellitus
Type
Interventional
Phase
Phase 3
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The study duration was approximately 29 weeks including 2 weeks screening period, 26 weeks open label treatment period, and a 3 days follow-up period.

The study duration was approximately 29 weeks including 2 weeks screening period, 26 weeks open label treatment period, and a 3 days follow-up period.

Tracking Information

NCT #
NCT03434119
Collaborators
Not Provided
Investigators
Study Director: Clinical Sciences & Operations Sanofi